Harnessing RNA reprogramming for cancer immunotherapy

Cell identity and function are classically controlled by cell type-specific transcription factors which activate the expression of target genes. However, RNA-level regulatory mechanisms co-regulate this process and have been previously used to supplement or enable cell reprogramming approaches. My PhD project centers on dendritic cell reprogramming driven by transcription factors PU.1, IRF8 and BATF3, which was previously described by our group. Specifically, I am exploring how miRNAs and RNA modifiers could be used to enhance this process. I have discovered promising candidates in both categories and am working to confirm and explain their action. I am also working on developing an efficient RNA-only dendritic cell reprogramming protocol as a safe and scaleable alternative to lentiviral delivery.